CAS 1173976-40-3 Gefitinib-[d3] - Isotope / BOC Sciences

General Information
Catalog: BLP-012680
CAS: 1173976-40-3
Molecular Formula: C22H21D3ClFN4O3
Molecular Weight: 449.92

General Information

Catalog: BLP-012680

CAS: 1173976-40-3

Molecular Formula: C22H21D3ClFN4O3

Molecular Weight: 449.92

Chemical Structure

Description	Gefitinib-[d3] is the labelled analogue of Gefitinib. Gefitinib is an EGFR inhibitor. It is used for the treatment of certain breast, lung and other cancers.
Synonyms	Gefitinib D3; N-(3-Chloro-4-fluorophenyl)-7-(methoxy-d3)-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
IUPAC Name	N-(3-chloro-4-fluorophenyl)-6-(3-morpholin-4-ylpropoxy)-7-(trideuteriomethoxy)quinazolin-4-amine
Related CAS	184475-35-2 (unlabelled)
Canonical SMILES	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
InChI	InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)/i1D3
InChI Key	XGALLCVXEZPNRQ-FIBGUPNXSA-N
Boiling Point	586.8±0.0 °C at 760 mmHg
Melting Point	193-196°C
Purity	98% by HPLC; 99% atom D
Density	1.3±0.0 g/cm3
Solubility	Soluble in Acetone, DMSO, Methanol
Appearance	Off-white to Light Beige Solid
Storage	Store at -20°C

Gefitinib-[d3], a deuterium-labeled derivative of gefitinib extensively utilized in cancer therapy, presents a myriad of applications in the field. Here are the key applications:

Pharmacokinetics Studies: Imbuing pharmacokinetic research with the incorporation of Gefitinib-[d3] unveils profound insights into the intricate dynamics of absorption, distribution, metabolism, and excretion of gefitinib. The deuteration attribute facilitates meticulous tracking and quantification through mass spectrometry, providing a holistic comprehension of the drug's behavior within the physiological milieu. This acquired knowledge serves as a cornerstone for optimizing dosing regimens to amplify therapeutic efficacy and outcomes.

Mechanistic Studies: Within the domain of cancer biology, researchers harness the potential of Gefitinib-[d3] to untangle the convoluted mechanisms of action and resistance in malignant cells. Through meticulous comparative analyses between gefitinib and its deuterium-tagged derivative, scientists delve deep into the intricate interplay between the drug and its target, the epidermal growth factor receptor (EGFR). This profound understanding stands as a linchpin for enhancing therapeutic effectiveness and overcoming the hurdles of drug resistance.

Drug-Drug Interaction Studies: Positioned as a pivotal instrument in dissecting potential drug interactions, Gefitinib-[d3] assumes a critical role in both preclinical and clinical investigations. The distinctive mass of the deuterium-labeled compound empowers researchers to discern between gefitinib and concomitantly administered drugs, a vital aspect in evaluating the safety and efficacy of combination therapies. This insightful differentiation aids in formulating judicious decisions regarding patient-centric treatment strategies, elevating the standards of therapeutic care.

Bioanalytical Assays: Nestled within the realm of bioanalytical chemistry, Gefitinib-[d3] emerges as a foundational internal standard for precise quantification of gefitinib in diverse biological samples. Its inclusion serves as a bedrock for ensuring accuracy and reproducibility in quantifying gefitinib concentrations in plasma, urine, and tissue specimens. This unparalleled level of precision plays a pivotal role in drug development and therapeutic monitoring, heralding a new era of clinical practices infused with cutting-edge analytical capabilities.